Boston, MA – According to filings with the U.S. Securities and Exchange Commission, PIC Therapeutics is raising $11,480,594.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Sun Altbach played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PIC Therapeutics

PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. Our precision-based therapeutics target the master switch of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. PIC Therapeutics’ selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.

To learn more about PIC Therapeutics, visit http://www.pictherapeutics.com/

Contact:
Sun Altbach, President and Chief Executive Officer
617-637-3738
https://www.linkedin.com/in/sun-altbach-9aaa321/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved